ArticleAIDS research and treatment2026
Calprotectin Levels in HIV-Infected Patients: Correlations With Disease Progression and Intestinal Inflammation.
Article in AIDS research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Calprotectin Levels in HIV-Infected Patients: Correlations With Disease Progression and Intestinal Inflammation.AIDS research and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent intestinal inflammation remains a significant concern in HIV-infected patients despite effective antiretroviral therapy (ART). Calprotectin (S100A8/A9), a calcium-binding protein complex involved in inflammatory signaling, has emerged as a potential biomarker in various inflammatory disorders; however, its role in HIV-related intestinal inflammation has not been extensively studied. Methods: This study recruited 15 AIDS-stage patients, 15 asymptomatic HIV-infected patients, and 10 healthy controls from Chengdu Anal and Intestinal Specialized Hospital between April and August 2023. Serum, fecal samples, and colonic mucosal biopsies were collected. Calprotectin expression was quantified using enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, and Western blot analysis. Histopathological evaluation was performed using hematoxylin and eosin staining. Statistical correlations between calprotectin levels and clinical indicators, including CD4+ T-cell counts, were analyzed. Results: Serum and fecal calprotectin concentrations were significantly elevated in HIV-infected groups compared with controls, with the highest levels observed in AIDS-stage patients ( Conclusions: Calprotectin serves as a sensitive biomarker reflecting intestinal inflammation severity and immune dysfunction in HIV-infected individuals. Serum and fecal calprotectin assays offer noninvasive, reliable methods for evaluating disease progression and inflammatory status and potentially guiding clinical management in HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.